Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Cantrixil

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kazia Therapeutics Sells Cantrixil IP and Trademarks for Cantrixil
    Kazia Therapeutics Sells Cantrixil IP and Trademarks for Cantrixil

    31 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-sale-of-intellectual-property-and-trademarks-rights-for-cantrixil-302415424.html

    PR NEWSWIRE
    31 Mar 2025
    Share Share
    Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
    Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug

    22 Mar 2022

    // S. Koltrowitz REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/lonza-signs-manufacturing-agreement-with-oasmia-ovarian-cancer-drug-2022-03-21/

    S. Koltrowitz REUTERS
    22 Mar 2022
    Share Share
    Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal
    Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal

    01 Mar 2021

    // PHARMAFILE

    http://www.pharmafile.com/news/571751/oasmia-acquires-rights-cancer-drug-candidate-cantrixil-44m-deal

    PHARMAFILE
    01 Mar 2021
    Share Share
    Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia
    Kazia Licenses Cantrixil, a Clinical-stage Ovarian Cancer Drug, to Oasmia

    01 Mar 2021

    // PRNASIA

    https://en.prnasia.com/releases/apac/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab-310003.shtml

    PRNASIA
    01 Mar 2021
    Share Share